MA53145A - Agents de liaison cd123 et leurs utilisations - Google Patents

Agents de liaison cd123 et leurs utilisations

Info

Publication number
MA53145A
MA53145A MA053145A MA53145A MA53145A MA 53145 A MA53145 A MA 53145A MA 053145 A MA053145 A MA 053145A MA 53145 A MA53145 A MA 53145A MA 53145 A MA53145 A MA 53145A
Authority
MA
Morocco
Prior art keywords
liaison
agents
liaison agents
Prior art date
Application number
MA053145A
Other languages
English (en)
Inventor
Ricardo Attar
Francois Gaudet
Benjamin C Harman
Yingzhe Li
Jinquan Luo
Ronan Mcdaid
Jennifer F Nemeth
Steven C Pomerantz
Susan H Tam
Alexey Teplyakov
John Wheeler
Sheng-Jiun Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53145A publication Critical patent/MA53145A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
MA053145A 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations MA53145A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05

Publications (1)

Publication Number Publication Date
MA53145A true MA53145A (fr) 2021-05-19

Family

ID=54150667

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40609A MA40609B1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations
MA053145A MA53145A (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40609A MA40609B1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Country Status (39)

Country Link
US (1) US9850310B2 (fr)
EP (2) EP3722315A1 (fr)
JP (2) JP6805130B2 (fr)
KR (1) KR102540192B1 (fr)
CN (1) CN107074956B (fr)
AR (1) AR101765A1 (fr)
AU (1) AU2015311931B2 (fr)
CA (1) CA2959171C (fr)
CL (1) CL2017000515A1 (fr)
CO (1) CO2017002196A2 (fr)
CR (1) CR20170079A (fr)
CY (1) CY1122858T1 (fr)
DK (1) DK3189081T3 (fr)
EA (1) EA037647B1 (fr)
EC (1) ECSP17020812A (fr)
ES (1) ES2791249T3 (fr)
HR (1) HRP20200745T1 (fr)
HU (1) HUE048791T2 (fr)
IL (1) IL250770B (fr)
JO (1) JO3568B1 (fr)
LT (1) LT3189081T (fr)
MA (2) MA40609B1 (fr)
ME (1) ME03724B (fr)
MX (1) MX384424B (fr)
MY (1) MY186337A (fr)
NI (1) NI201700025A (fr)
PE (1) PE20171556A1 (fr)
PH (1) PH12017500472A1 (fr)
PL (1) PL3189081T3 (fr)
PT (1) PT3189081T (fr)
RS (1) RS60305B1 (fr)
SG (1) SG11201701599UA (fr)
SI (1) SI3189081T1 (fr)
SM (1) SMT202000253T1 (fr)
TW (1) TWI693233B (fr)
UA (1) UA120060C2 (fr)
UY (1) UY36289A (fr)
WO (1) WO2016036937A1 (fr)
ZA (1) ZA201702369B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
EP3297672B1 (fr) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
HRP20251020T1 (hr) * 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP6921943B2 (ja) 2016-06-06 2021-08-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増加した眼球保持を伴う眼科用融合タンパク質
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
EP3515491A4 (fr) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC Protéines de liaison à cd123 et compositions et procédés associés
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018145075A1 (fr) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour augmenter la signalisation de récepteurs médiée par des anticorps
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
WO2018166461A1 (fr) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019050521A1 (fr) * 2017-09-07 2019-03-14 Macrogenics, Inc. Schémas posologiques de diacorps bispécifiques cd123 x cd3 dans le traitement de malignités hématologiques
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (fr) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Proteines trispecifiques et methodes d'utilisation
WO2019082020A1 (fr) * 2017-10-27 2019-05-02 Pfizer Inc. Anticorps et conjugués anticorps-médicament spécifiques à cd123 et leurs utilisations
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
WO2019220368A1 (fr) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020080853A1 (fr) * 2018-10-17 2020-04-23 주식회사 굳티셀 Molécule de liaison spécifique à la protéine lrig-1, et utilisation associée
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN119954959A (zh) * 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法
WO2020232303A1 (fr) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. Protéines de liaison à epcam et méthodes d'utilisation
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN113912696B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与其应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
PE20231517A1 (es) 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
TW202207977A (zh) * 2020-05-19 2022-03-01 美商健生生物科技公司 包含ｔ細胞重導向治療劑及ｖｌａ－４黏附路徑抑制劑之組成物
JP7770339B2 (ja) 2020-05-19 2025-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を誘導するためのコンジュゲートポリペプチドおよびワクチン
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
CA3202891A1 (fr) 2021-01-28 2022-08-04 Kara Olson Compositions et methodes de traitement du syndrome de liberation de cytokines
JP2024518200A (ja) * 2021-05-18 2024-04-30 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物
WO2022245500A1 (fr) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Polypeptides d'il-21 et constructions ciblées
EP4384218A4 (fr) * 2021-08-09 2025-11-05 Merck Patent Gmbh Protéines désaccouplant la cytotoxicité tumorale à médiation par les lymphocytes t de la libération de cytokines pro-inflammatoires
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023227790A1 (fr) 2022-05-27 2023-11-30 Sanofi Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2025167631A1 (fr) 2024-02-05 2025-08-14 北京三诺佳邑生物技术有限责任公司 Anticorps multi-spécifique se liant de manière spécifique à l'antigène pré-s1 du vhb, à l'antigène pd-l1 et à l'antigène cd3 et son utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
ES2550639T3 (es) * 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2010298036B2 (en) * 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2850106B1 (fr) * 2012-05-18 2022-03-23 Aptevo Research and Development LLC Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3

Also Published As

Publication number Publication date
EA037647B1 (ru) 2021-04-27
IL250770B (en) 2020-10-29
BR112017004322A2 (pt) 2017-12-05
AU2015311931A1 (en) 2017-03-16
SI3189081T1 (sl) 2020-07-31
JP2021050216A (ja) 2021-04-01
KR20170049554A (ko) 2017-05-10
IL250770A0 (en) 2017-04-30
EP3722315A1 (fr) 2020-10-14
ECSP17020812A (es) 2018-07-31
HRP20200745T1 (hr) 2020-08-07
ES2791249T3 (es) 2020-11-03
PH12017500472A1 (en) 2017-07-31
MX2017002891A (es) 2017-10-11
PL3189081T3 (pl) 2020-10-05
US20160068605A1 (en) 2016-03-10
UY36289A (es) 2016-04-01
CA2959171A1 (fr) 2016-03-10
CL2017000515A1 (es) 2018-03-16
TW201625687A (zh) 2016-07-16
RS60305B1 (sr) 2020-07-31
MA40609B1 (fr) 2020-05-29
EP3189081A1 (fr) 2017-07-12
UA120060C2 (uk) 2019-09-25
TWI693233B (zh) 2020-05-11
MX384424B (es) 2025-03-14
PT3189081T (pt) 2020-05-25
JP2017529838A (ja) 2017-10-12
CN107074956A (zh) 2017-08-18
AU2015311931B2 (en) 2020-09-03
MY186337A (en) 2021-07-13
NI201700025A (es) 2017-06-22
DK3189081T3 (da) 2020-05-04
WO2016036937A1 (fr) 2016-03-10
ME03724B (fr) 2021-01-20
JP6805130B2 (ja) 2020-12-23
LT3189081T (lt) 2020-05-11
EP3189081B1 (fr) 2020-02-19
AR101765A1 (es) 2017-01-11
KR102540192B1 (ko) 2023-06-02
CY1122858T1 (el) 2021-05-05
CO2017002196A2 (es) 2017-07-28
PE20171556A1 (es) 2017-10-27
HUE048791T2 (hu) 2020-09-28
SG11201701599UA (en) 2017-03-30
ZA201702369B (en) 2018-12-19
EA201790530A1 (ru) 2018-03-30
SMT202000253T1 (it) 2020-07-08
CA2959171C (fr) 2023-11-14
JO3568B1 (ar) 2020-07-05
CN107074956B (zh) 2021-11-26
CR20170079A (es) 2017-04-27
US9850310B2 (en) 2017-12-26

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
MA50618A (fr) Polyrhérapies et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3344275A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3337486A4 (fr) Composés deutérés et leurs utilisations
BR112017019682A2 (pt) fluoropolímeros modificados
EP3294318A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3334572A4 (fr) Exosquelette
EP3333833A4 (fr) Simulateur de technique
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3302490A4 (fr) Inhibiteurs d'autotaxine et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
EP3370771A4 (fr) Conjugués anti-cd3-folate et leurs utilisations
EP3450444A4 (fr) Composés de type crocine et utilisations correspondantes
EP3377897A4 (fr) Biocapteurs de lactate et leurs utilisations
EP3405044A4 (fr) Composition bioconservatrice alimentaire et ses utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
EP3459937A4 (fr) Dérivé de thiazole et utilisations